Intellia Therapeutics (NTLA) Receivables (2016 - 2025)
Historic Receivables for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to $11.0 million.
- Intellia Therapeutics' Receivables rose 2480.23% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year increase of 2480.23%. This contributed to the annual value of $8.5 million for FY2024, which is 7726.13% down from last year.
- According to the latest figures from Q3 2025, Intellia Therapeutics' Receivables is $11.0 million, which was up 2480.23% from $11.4 million recorded in Q2 2025.
- Intellia Therapeutics' Receivables' 5-year high stood at $37.5 million during Q4 2023, with a 5-year trough of $1.8 million in Q1 2022.
- Over the past 5 years, Intellia Therapeutics' median Receivables value was $6.5 million (recorded in 2023), while the average stood at $9.5 million.
- Per our database at Business Quant, Intellia Therapeutics' Receivables plummeted by 9102.81% in 2021 and then skyrocketed by 59776.45% in 2023.
- Over the past 5 years, Intellia Therapeutics' Receivables (Quarter) stood at $2.1 million in 2021, then surged by 151.9% to $5.4 million in 2022, then surged by 597.76% to $37.5 million in 2023, then tumbled by 77.26% to $8.5 million in 2024, then increased by 29.74% to $11.0 million in 2025.
- Its last three reported values are $11.0 million in Q3 2025, $11.4 million for Q2 2025, and $10.5 million during Q1 2025.